These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Tuberous and tendinous xanthomata secondary to ritonavir-associated hyperlipidemia. Brown CA; Lesher JL; Peterson CM J Am Acad Dermatol; 2005 May; 52(5 Suppl 1):S86-9. PubMed ID: 15858517 [TBL] [Abstract][Full Text] [Related]
27. Can delavirdine substitute for ritonavir? TreatmentUpdate; 2001; 13(7):8. PubMed ID: 11794866 [No Abstract] [Full Text] [Related]
28. Possible fatal interaction between protease inhibitors and methamphetamine. Hales G; Roth N; Smith D Antivir Ther; 2000 Mar; 5(1):19. PubMed ID: 10846588 [No Abstract] [Full Text] [Related]
29. Type 2 diabetes in association with HIV-1 protease inhibitors in HIV-infected patients. Chronister CL; Gurwood AS J Am Optom Assoc; 1998 Nov; 69(11):695-8. PubMed ID: 9844321 [No Abstract] [Full Text] [Related]
30. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks. Kosalaraksa P; Bunupuradah T; Engchanil C; Boonrak P; Intasan J; Lumbiganon P; Burger D; Ruxrungtham K; Schutz M; Ananworanich J; Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443 [TBL] [Abstract][Full Text] [Related]
32. Dramatic interaction between levothyroxine and lopinavir/ritonavir in a HIV-infected patient. Touzot M; Beller CL; Touzot F; Louet AL; Piketty C AIDS; 2006 May; 20(8):1210-2. PubMed ID: 16691080 [No Abstract] [Full Text] [Related]
33. Hair loss in an HIV-1 infected woman receiving lopinavir plus ritonavir therapy as first line HAART. Bongiovanni M; Chiesa E; Monforte Ad; Bini T Dermatol Online J; 2003 Dec; 9(5):28. PubMed ID: 14996401 [No Abstract] [Full Text] [Related]
34. Ritonavir-boosted protease inhibitors: impact of ritonavir on toxicities in treatment-experienced patients. Sension M; Piliero PJ J Assoc Nurses AIDS Care; 2007; 18(1):36-47. PubMed ID: 17338984 [TBL] [Abstract][Full Text] [Related]